OS4.6 Large-scale radiomic profiling of recurrent glioblastoma identifies an imaging predictor for stratifying anti-angiogenic treatment response

BACKGROUND: Antiangiogenic treatment with bevacizumab, a monoclonal antibody to the vascular endothelial growth factor, is the single most widely used therapeutic agent for patients with recurrent glioblastoma (GB). A major challenge is that there are currently no validated biomarkers that can predi...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Neuro Oncol
Hoofdauteurs: Kickingereder, P., Götz, M., Wick, A., Neuberger, U., Schlemmer, H., Radbruch, A., Wick, W., Bendszus, M., Maier-Hein, K., Bonekamp, D.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2016
Onderwerpen:
OS4 Biomarker
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5782532/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now188.032
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items